Lisa Jones-Engel*

, Cynthia C. May†, Gregory A. Engel*‡, Katherine A. Steinkraus†, Michael A. Schillaci, Agustin Fuentes¶, Aida Rompis#, Mukesh K. Chalise**, Nantiya Aggimarangsee††, Mohammed M. Feeroz‡‡, Richard Grant*
1, Jonathan S. Allan§§, Arta Putra#, I. Nengah Wandia#, Robin Watanabe*, LaRene Kuller*, Satawat Thongsawat††, Romanee Chaiwarith††, Randall C. Kyes*, and Maxine L. Linial†
Author affiliations: *University of Washington, Seattle, Washington, USA; †Fred Hutchinson Cancer Research Center, Seattle; ‡Swedish Hospital, Seattle; §University of Toronto, Scarborough, Toronto, Ontario, Canada; ¶Notre Dame University, Notre Dame, Indiana, USA; #Universitas Udayana, Denpasar, Bali, Indonesia; **Tribhuvan University, Kathmandu, Nepal; ††Chiang Mai University, Chiang Mai, Thailand; ‡‡Jahangirnagar University, Savar, Dhaka, Bangladesh; §§Southwest Foundation for Biomedical Research, San Antonio, Texas, USA;
Main Article
Table 2
Persons at high risk for SFV, Asia*
| Country | No. samples tested | No. ELISa reactive | No. WB positive | No. SFV sequences derived | Total no. confirmed
SFV positive |
|---|
| Thailand | 211† | 15 | 3 | NA | 3 |
| Nepal | 9 | 1 | 1 | NA | 1 |
| Indonesia | 74 | 8 | 3 | 2 | 3 |
Bangladesh
| 11
| 1
| 1
| 1
| 1
|
| Total | 305 | 25 | 8 | 3 | 8 (2.6%) |
Main Article
Top of Page